Citations

Showing 10 of 108162 citations.

Disease Profile and Oncologic Outcomes After Delayed Diagnosis of Human Papillomavirus–Associated Oropharyngeal Cancer
Karp, Emily E. , Elias, Anna , O’Byrne, Thomas J., Routman, David M. , Kasperbauer, Jan L. , Neben-Wittich, M.A. , Price, Katharine A. , Foote, Robert L. , Moore, Eric J. , Abel, Kathryn M. Van , O'Byrne, Thomas J, Neben-Wittich, Michelle, Van Abel, Kathryn M , Routman, David M , Yin, Linda X. , Price, Daniel L. , Chintakuntlawar, Ashish V. , Daniel, J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | March 23, 2021 | Volume: 165 | Issue: 6 | Pages: 830-837

10.1177/01945998211000426 | PMID 33752487 Get It

ObjectiveDiagnostic delay in human papillomavirus–associated oropharynx squamous cell carcinoma (HPV(+)OPSCC) is common due to nonspecific symptoms. We aim to describe the disease burden and oncologic outcomes of patients with HPV(+)OPSCC diagnosed >12 months after symptom onset.Study DesignThis is a retrospective cohort study of HPV(+)OPSCC patients receiving intent‐to‐cure treatment (including surgery ± adjuvant therapy or primary chemoradiation).Setting2006‐2016, tertiary care center.MethodsTumor stage was compared between patients with and without delayed diagnosis using χ2 tests. Kaplan‐Meier survival analysis with univariate and multivariable Cox regressions were used to determine the effect of diagnostic delay on oncologic outcomes.ResultsIn total, 664 patients were included. Compared to patients diagnosed <12 months from symptom onset (n = 601), those diagnosed at >12 months (n = 63) were more likely to have T4 disease and higher overall American Joint Committee on Cancer (AJCC) clinical stage at presentation (P <. 01 for both). At 5 years, rates of overall survival, cancer‐specific survival, progression‐free survival, and distant metastases–free survival in the delayed diagnosis cohort were 80%, 90%, 80%, and 89%, respectively. A >12‐month delay in diagnosis did not significantly impact overall survival (adjusted hazard ratio [aHR], 1.16; 95% CI, 0.58‐2.31), cancer‐specific survival (aHR, 0.83; 95% CI, 0.29‐2.39), progression‐free survival (aHR, 1.15; 95% CI, 0.56‐2.37), or distant metastases–free survival (aHR, 1.00; 95% CI, 0.42‐2.40) after adjusting for age, sex, and clinical AJCC stage (P >. 05 for all).ConclusionsDelayed diagnosis of HPV(+)OPSCC is associated with greater burden of disease at presentation, but oncologic outcomes remain favorable across treatment modalities. When appropriate, intent‐to‐cure therapy should be pursued despite diagnostic delay.Level of EvidenceLevel III.
Rectosigmoid resection by gynecologic oncologists versus colorectal surgeons: as long as it catches the mouse, does the color of the cat matter?
Chang, Suk‐Joon , Fotopoulou, Christina , Bristow, Robert E. , Dennis, S. , Cliby, William A. , Chi, Dennis S , Cliby, William A

Mayo Clinic

Journal of Gynecologic Oncology | March 23, 2021 | Volume: 32 | Issue: 3 | Pages: No page available

10.3802/jgo.2021.32.e51 | PMID 33825361 Get It

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
Rogers, Kerry A. , Andritsos, Leslie A. , Wei, Lai , McLaughlin, Eric , Ruppert, Amy S. , Anghelina, Mirela , Blachly, James S. , Call, Timothy G. , Chihara, Dai , Dauki, Anees M. , James, Lacey, Kreitman, Robert J. , Lozanski, Gerard , Lucas, David , Ngankeu, Apollinaire, Phelps, Mitch A. , Schiffer, Charles A. , Carson, William E. , Jones, Jeffrey A. , Grever, Michael R. , Call, Timothy, Dauki, Anees , Carson, William E , Wei, Lai , Chihara, Dai , Blachly, James , Phelps, Mitch , Guo, Ling Jun , Ivy, S. Percy , Jones, Daniel R. , Ravandi, Farhad

Mayo Clinic

Blood | March 23, 2021 | Volume: 137 | Issue: 25 | Pages: 3473-3483

10.1182/blood.2020009688 | PMID 33754642 Get It

Abstract Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is highly effective in several malignancies. Its activity in HCL was unknown, so we conducted a multisite phase 2 study of oral ibrutinib in patients with either relapsed classic or variant hairy cell leukemia. The primary outcome measure was the overall response rate (ORR) at 32 weeks, and we also assessed response at 48 weeks and best response during treatment. Key secondary objectives were characterization of toxicity and determination of progression-free survival (PFS) and overall survival (OS). Thirty-seven patients were enrolled at 2 different doses (24 at 420 mg, 13 at 840 mg). The median duration of follow-up was 3.5 years (range, 0-5.9 years). The ORR at 32 weeks was 24%, which increased to 36% at 48 weeks. The best ORR was 54%. The estimated 36-month PFS was 73% and OS was 85%. The most frequent adverse events were diarrhea (59%), fatigue (54%), myalgia (54%), and nausea (51%). Hematologic adverse events were common: anemia (43%), thrombocytopenia (41%), and neutropenia (35%). Ibrutinib can be safely administered to patients with HCL with objective responses and results in prolonged disease control. Although the initial primary outcome objective of the study was not met, the observation of objective responses in heavily pretreated patients coupled with a favorable PFS suggests that ibrutinib may be beneficial in these patients. This trial was registered at www.clinicaltrials.gov as #NCT01841723.
Pleuroperitoneal (Denver) Shunt for Recurrent Nonmalignant Breast Seroma in a Metastatic Breast Cancer Patient
Pflibsen, Lacey R. , Velazco, Cristine S. , Rhee, Daniel H. , Bryant, Lyndsey A. , Chapital, Alyssa B. , Rebecca, Alanna M.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | March 22, 2021 | Volume: 8 | Issue: 6 | Pages: e2928

10.1097/gox.0000000000002928 | PMID 32766072 Get It

Summary: Pleuroperitoneal (Denver) shunts have been used primarily for palliation of refractory malignant and chylous peritoneal and pleural collections. 1–5 We used a pleuroperitoneal (Denver) shunt for a recurrent, nonmalignant breast seroma in the palliation of metastatic breast cancer as a novel use of this shunt.
BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systematic Review
Stack, Michael , Sacco, Keith , Castagnoli, Riccardo , Notarangelo, Luigi D , Sacco, Keith A , Livinski, Alicia A. , Lionakis, Michail S.

Mayo Clinic

No container title available | March 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-319342/v1 | PMID 33791689 Get It

Abstract ImportanceThe Bruton tyrosine kinase (BTK) regulates B cell and macrophage signaling, development, survival, and activation. BTK inhibition was shown to protect against lethal influenza-induced acute lung injury in mice. Inhibiting BTK has been hypothesized to ameliorate lung injury in patients with severe coronavirus disease 2019 (COVID-19). ObjectiveTo evaluate the use of BTK inhibitors (BTKinibs) during COVID-19 and assess how they may affect patient outcomes.Evidence ReviewWe searched PubMed, Embase, and Web of Science: Core on December 30, 2020. Clinical studies with at least 5 COVID-19 patients treated with BTKinibs were included. Case reports and reviews were excluded.FindingsOne hundred twenty-five articles were identified, 6 of which met inclusion criteria. Sample size ranged from 6 to 126 patients. Patient populations included subjects hospitalized with COVID-19 (6/6) and admitted to the intensive care unit (5/6). Patient age ranged between 35 and 98 years. Four studies included patients already receiving BTKinibs for their lymphoproliferative disease, 1 for Waldenstrom’s macroglobulinemia and 3 for chronic lymphocytic leukemia (CLL). The most common clinical outcomes measured were oxygen requirements (4/6) and hospitalization rate or duration (3/6). Differences in standard-of-care reflected the date of study and pre-existing conditions in the various patient cohorts. Full-dose acalabrutinib was evaluated in 2 studies, one study evaluated full-dose ibrutinib, and another study evaluated both ibrutinib and acalabrutinib. The remainder 2 studies described outcomes in CLL patients on multiple BTKinibs and other CLL-targeted treatments. Three studies showed decreased oxygen requirements in patients who started or continued BTKinibs. All three studies that evaluated hospitalization rate or duration found favorable outcomes in those on BTKinibs. Conclusions and RelevanceBTKinib use was associated with decreased oxygen requirements and decreased hospitalization rates and duration. However, randomized clinical trials are needed to validate the beneficial effects of BTKinibs for acute SARS-CoV-2 infection.
Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy
Singh, Nina, Winston, Drew J., Lyon, G. Marshall, Silveira, Fernanda P. , Wagener, Marilyn M., Razonable, Raymund R. , Limaye, Ajit P.

Mayo Clinic

The Journal of Infectious Diseases | March 22, 2021 | Volume: 225 | Issue: 3 | Pages: 436-442

10.1093/infdis/jiab132 | PMID 33755176 Get It

Abstract Background Detailed cytomegalovirus (CMV) kinetics in donor CMV-seropositive, recipient CMV-seronegative (D+/R–) transplant recipients receiving preemptive therapy (PET) have not been fully defined. Methods The study population consisted of the PET arm of a randomized CMV prevention trial in D+/R– liver transplant recipients. CMV DNA polymerase chain reaction (PCR) assays were performed weekly for 100 days using a sensitive assay. Viral load and clinical parameters were compared for patients with or without high-level increase (defined as higher than the group median log10 increase in viral load from baseline after PET initiation). Results Among 79 patients, 93.6% (74/79) developed an increase from baseline viral loads of median 120 IU/mL to 3350 IU/mL; 25.7% (19/74) of the patients had peak levels &gt;10 000 IU/mL. None of the patients with rise in viral load underwent testing for CMV resistance, and viremia resolved with PET with valganciclovir. Patients with high-level increase in viral load had a significantly lower rate of recurrent viremia than those without such increase (16/40 [40%] vs 28/39 [71.8%], respectively; P = .004). Conclusions A majority of D+/R– recipients had a marked increase in viral load after initiation of PET before resolution of viremia. This phenomenon is associated with lower rates of subsequent recurrent viremia and does not necessarily imply antiviral resistance.
Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations
Ho, Alan L. , Braña, Irene , Haddad, Robert I. , Bauman, Jessica R. , Bible, Keith C. , Oosting, Sjoukje F. , Wong, Deborah Jean Lee, Ahn, Myung‐Ju , Even, Caroline , Flor, M.J. , Harrington, Kevin J. , Licitra, Lisa , Nixon, Ioanna , Balsara, Binaifer, Leoni, Mollie , Martell, Bridget, Scholz, Catherine, Gualberto, Antonio , Haddad, Robert , Bible, Keith C , Boni, Valentina , Harrington, Kevin , Kim, Sung-Bae , Licitra, Lisa , Saba, Nabil F , Gualberto, Antonio , Ho, Alan L , Fayette, Jérôme , Hong, David S. , Saba, Nabil F. , Hackenberg, Stephan , Specenier, Pol M. , Worden, Francis P.

Mayo Clinic

Journal of Clinical Oncology | March 22, 2021 | Volume: 39 | Issue: 17 | Pages: 1856-1864

10.1200/jco.20.02903 | PMID 33750196 Get It

PURPOSEMutations in the HRAS (m HRAS) proto-oncogene occur in 4%-8% of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Tipifarnib is a farnesyltransferase inhibitor that disrupts HRAS function. We evaluated the efficacy of tipifarnib in patients with R/M m HRAS HNSCC.METHODSWe enrolled 30 patients with R/M HNSCC in a single-arm, open-label phase II trial of tipifarnib for m HRAS malignancies; one additional patient was treated on an expanded access program. After an ad hoc analysis of the first 16 patients with HNSCC with m HRAS variant allele frequency (VAF) data, enrollment was limited to those with a m HRAS VAF of ≥ 20% (high VAF). The primary end point was objective response rate. Secondary end points included assessing safety and tolerability. Patients received tipifarnib 600 or 900 mg orally twice daily on days 1-7 and 15-21 of 28-day cycles.RESULTSOf the 22 patients with HNSCC with high VAF, 20 were evaluable for response at the time of data cutoff. Objective response rate for evaluable patients with high-VAF HNSCC was 55% (95% CI, 31.5 to 76.9). Median progression-free survival on tipifarnib was 5.6 months (95% CI, 3.6 to 16.4) versus 3.6 months (95% CI, 1.3 to 5.2) on last prior therapy. Median overall survival was 15.4 months (95% CI, 7.0 to 29.7). The most frequent treatment-emergent adverse events among the 30 patients with HNSCC were anemia (37%) and lymphopenia (13%).CONCLUSIONTipifarnib demonstrated encouraging efficacy in patients with R/M HNSCC with HRAS mutations for whom limited therapeutic options exist ( NCT02383927 ).
Three-dimensional Printing in Plastic Surgery: Current Applications, Future Directions, and Ethical Implications
Lynn, Alex, Smith, Anthony A., Rebecca, Alanna M. , Teven, Chad M. , Pflibsen, Lacey R.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | March 22, 2021 | Volume: 9 | Issue: 3 | Pages: e3465

10.1097/gox.0000000000003465 | PMID 33968548 Get It

Background: Three-dimensional printing (3DP) is a rapidly advancing tool that has revolutionized plastic surgery. With ongoing research and development of new technology, surgeons can use 3DP for surgical planning, medical education, biological implants, and more. This literature review aims to summarize the currently published literature on 3DP’s impact on plastic surgery. Methods: A literature review was performed using Pubmed and MEDLINE from 2016 to 2020 by 2 independent authors. Keywords used for literature search included 3-dimensional (3D), three-dimensional printing (3DP), printing, plastic, surgery, applications, prostheses, implants, medical education, bioprinting, and preoperative planning. All studies from the database queries were eligible for inclusion. Studies not in English, not pertaining to plastic surgery and 3DP, or focused on animal data were excluded. Results: In total, 373 articles were identified. Sixteen articles satisfied all inclusion and exclusion criteria, and were further analyzed by the authors. Most studies were either retrospective cohort studies, case reports, or case series and with 1 study being prospective in design. Conclusions: 3DP has consistently shown to be useful in the field of plastic surgery with improvements on multiple aspects, including the delivery of safe, effective methods of treating patients while improving patient satisfaction. Although the current technology may limit the ability of true bioprinting, research has shown safe and effective ways to incorporate biological material into the 3D printed scaffolds or implants. With an overwhelmingly positive outlook on 3DP and potential for more applications with updated technology, 3DP shall remain as an effective tool for the field of plastic surgery.
“Orphan” Status: Inadequate Protection for Abandoned Residents
Adler, Cameron, Adler, Cameron

Mayo Clinic

Academic Medicine | March 22, 2021 | Volume: 95 | Issue: 4 | Pages: 488-488

10.1097/acm.0000000000003166 | PMID 32209843 Get It